Full-Time

Research Scientist

Biophysics / Molecular Interactions

Posted on 8/15/2024

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Discovers and develops therapeutic antibodies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$75.2k - CA$94kAnnually

+ Equity + Annual Bonus

Senior

Vancouver, BC, Canada

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • You have a PhD in Biophysics, Biochemistry, or Structural Biology, or a MSc degree plus 5+ years of relevant experience
  • You have demonstrated experience using Carterra, Biacore, and Octet platforms to characterize protein binding kinetics, affinity and epitope
  • You have experience running plate based assays, analyzing large data sets, and interpreting and communicating data in the context of broader project objectives
  • You have impeccable attention to detail with excellent documentation and organizational skills
  • You have effective decision-making and troubleshooting skills, with impeccable attention to detail
  • You have great interpersonal skills with the ability to work collaboratively as a member of cross-functional team
  • You have experience using analytical techniques such as UHPLC, light scattering or mass spectrometry to assess reagent quality and aid in the interpretation of binding data (desirable)
  • You have experience using automated liquid handlers, or other molecular interaction technologies such as kinetic exclusion assay (KinExA), enzyme-linked immunosorbent assay (ELISA), or isothermal titration calorimetry (ITC) (desirable)
Responsibilities
  • Using biosensor based technologies such as surface plasmon resonance (SPR) or biolayer interferometry (BLI) to rapidly screen through hundreds to thousands of candidate antibodies to identify lead molecules with desired kinetic, affinity and epitope profiles
  • Conducting detailed characterization of the kinetics, affinity, and mechanism of action of lead molecules, including for example, assessing pH-dependent binding, Fc effector function, and other critical properties
  • Evaluating the properties of bispecific antibodies and other multispecific molecules, in support of lead selection and optimization
  • Developing high throughput workflows for antibody kinetic and epitope analysis, and automating these workflows using liquid handlers
  • Working with data scientists, machine learning and software engineers to streamline the capture, curation and analysis of large data sets
  • Collaborating with teammates from discovery biology, protein engineering and other teams to build platforms and processes, as well as analyze, interpret and communicate data
  • Providing protein science and biotherapeutic leadership within multidisciplinary drug discovery teams
  • Mentoring and developing junior scientists within a rapidly growing and dynamic team

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and its own therapeutic programs.

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could lead to breakthroughs in neurological treatments.
  • Partnership with Eli Lilly expands AbCellera's reach in diverse therapeutic areas.
  • Acquisition of Dualogics' platform strengthens AbCellera's competitive position.

What critics are saying

  • Peter Thiel's resignation may impact strategic guidance and investor confidence.
  • High-risk research with Biogen could lead to delays or failures.
  • Resource allocation challenges may arise from multiple new biotech ventures.

What makes AbCellera Biologics unique

  • AbCellera's platform integrates diverse scientific approaches for efficient antibody discovery.
  • The company excels in tackling challenging targets with innovative methods.
  • AbCellera's strategic partnerships enhance its antibody development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

INACTIVE